CTLA4 and melanoma: Currently approved immunotherapies with ICIs for patients with melanoma include the following antibodies: (1) nivolumab and pembrolizumab against programmed death-1 (PD-1) and atezolizumab against its ligand (PD-L1), (2) ipilimumab against CTLA-4, and (3) relatlimab against lymphocyte-activation gene 3 (LAG-3), which are used as monotherapies or in specific combinations, also with other classes of antimelanoma therapies [30].